Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-6.81% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AUPH · Jun 30, 2023
Aurinia Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001600620-23-000029General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
47.19% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
79.90% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
96.23% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-38.97% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
30.49% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
29.57% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesSelf-history eligible
Mar 31, 20210/6 normalizedLevel 3Jun 30, 20210/6 normalizedLevel 3Sep 30, 20210/6 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20225/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Sep 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -92.04%
- Current
- -6.81%
- Delta
- 85.23%
- Previous
- 59.12%
- Current
- 47.19%
- Delta
- -11.93%
- Previous
- 92.26%
- Current
- 79.90%
- Delta
- -12.35%
- Previous
- 98.78%
- Current
- 96.23%
- Delta
- -2.54%
- Previous
- -85.98%
- Current
- -38.97%
- Delta
- 47.01%
- Previous
- 38.24%
- Current
- 30.49%
- Delta
- -7.75%
- Previous
- 27.51%
- Current
- 29.57%
- Delta
- 2.05%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · AUPH Fundamental State →Analogous To · AUPH state analogue 3 →Has State · Aurinia Pharmaceuticals Inc. →Transitioned To · AUPH Fundamental State →Transitioned To · AUPH CASH_GENERATION_INCREASED →Transitioned To · AUPH GROWTH_DECREASED →Transitioned To · AUPH INVENTORY_PRESSURE_DECREASED →Transitioned To · AUPH MARGIN_DECREASED →Transitioned To · AUPH PROFITABILITY_INCREASED →Transitioned To · AUPH R_AND_D_INTENSITY_DECREASED →Transitioned To · AUPH SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.